No Data
Inner Mongolia Furui Medical Science (300049): Stock-based incentive expenses disturb Q3 profits, FibroScan volume expected to increase.
Event: The company released the third quarter report for 2024, achieving a revenue of 0.98 billion yuan in the first three quarters of 2024, a year-on-year increase of 21.42%, and a net income attributable to the parent company of 0.102 billion yuan, a year-on-year increase of 39.42%, net of non-recurring gains and losses.
Inner Mongolia Furui Medical Science (300049): Performance growth meets expectations. MASH drug 'water sellers' are quietly waiting for the flowers to bloom.
The company released the third quarter report for 2024. In the first three quarters of 2024, the company achieved revenue of 0.98 billion yuan, a year-on-year increase of +21.42%; net income attributable to the parent company was 0.102 billion yuan, a year-on-year increase of +39.42%; net income attributable to non-controlling interests
Inner Mongolia Furui Medical Science (300049): Stock-based incentive expenses affecting reported profits. Waiting patiently for the promotion of MASH treatment drugs.
Event: The company released the third quarter report of 2024, achieving operating income of 0.98 billion yuan in the first three quarters of 2024 (+21.42% year-on-year), net income attributable to the parent company of 0.102 billion yuan (+39.42% year-on-year), excluding non-recurring items.
Inner Mongolia Furui Medical Science Q3 Profit Down 6%; Shares Rise 6%
Inner Mongolia Furui Medical Science (300049): Looking forward to the clinical progress of Simegluramine MAFLD Phase III.
Event: In the first three quarters of 2024, Inner Mongolia Furui Medical Science achieved revenue of 0.98 billion yuan (+21.42%), net income attributable to the mother of 0.102 billion yuan (+39.42%), and non-GAAP net income attributable to the mother of 0.097 billion yuan (+
Furui shares: report for the third quarter of 2024
